• Jeffrey R Kugelman, Mariano Sanchez-Lockhart, Kristian G Andersen, Stephen Gire, Daniel J Park, Rachel Sealfon, Aaron E Lin, Shirlee Wohl, Pardis C Sabeti, Jens H Kuhn, and Gustavo F Palacios.
• Center for Genome Sciences Division of the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA.
• Mbio. 2015 Jan 20; 6 (1).

AbstractUntil recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of deaths. Recent studies revealed the genomic changes this particular EBOV variant undergoes over time during human-to-human transmission. Here we highlight the genomic changes that might negatively impact the efficacy of currently available EBOV sequence-based candidate therapeutics, such as small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and antibodies. Ten of the observed mutations modify the sequence of the binding sites of monoclonal antibody (MAb) 13F6, MAb 1H3, MAb 6D8, MAb 13C6, and siRNA EK-1, VP24, and VP35 targets and might influence the binding efficacy of the sequence-based therapeutics, suggesting that their efficacy should be reevaluated against the currently circulating strain.Copyright © 2015 Kugelman, et al.

21 keywords...

hide…